TCT 2022: Edwards' Pascal Matches Abbott's MitraClip In CLASP IID
Results of the CLASP IID trial showed Edwards’ Pascal mitral valve repair system was non-inferior for safety and effectiveness compared to Abbott’s MitraClip device.
You may also be interested in...
Part II of highlights the cardiovascular tech sectors includes news from Medtronic, Edwards Lifesciences, and Abbott, plus a look at the upcoming TCT Conference in Boston.
The late-breaking clinical trial presentations at this year’s Transcatheter Cardiovascular Therapeutics conference in Boston included new results from trials of three different minimally invasive approaches to treat uncontrolled hypertension.
This edition of Medtech Insight’s regular round-up of heart-tech news covers some highlights of this years’ Transcatheter Cardiovascular Therapeutics (TCT) meeting in September, including the latest trials of Abbott's Amulet left-atrial appendage closure device and Medtronic's Intrepid transcatheter mitral valve replacement.